Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amikacin liposomal - Gilead Sciences

Drug Profile

Amikacin liposomal - Gilead Sciences

Alternative Names: MiKasome®

Latest Information Update: 09 Oct 2000

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeXstar Pharmaceuticals
  • Developer Gilead Sciences
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis-associated respiratory tract infections; Mycobacterium avium complex infections; Nosocomial infections; Pseudomonal infections; Tuberculosis; Urinary tract infections

Most Recent Events

  • 10 Dec 2015 Biomarkers information updated
  • 09 Oct 2000 Discontinued-I for Mycobacterium avium complex infections in USA (Parenteral)
  • 09 Oct 2000 Discontinued-I for Tuberculosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top